DFIB Cardiac Science (MM)

Australia's Ventracor Appoints US-based Medical Device Veteran as COO to Lead Strategic Marketing, Sales and Distribution in USA and Europe SYDNEY, Feb. 18 /PRNewswire-FirstCall/ -- International medical technology company, Ventracor Limited (OTC:VTCRY)(ASX:VCR), today announced the immediate appointment of Mr. Peter Crosby as Chief Operating Officer to lead the company's strategic marketing, sales and distribution in Europe and the USA. Mr. Crosby will initially focus on marketing and sales of the VentrAssist(TM) left ventricular assist system (LVAS), as well as clinical trials and regulatory approvals. He brings to Ventracor more than 20 years experience in the global commercialisation of cardiac medical devices and specialist skills in product development, marketing, strategic planning and business development. "We are pleased Ventracor has attracted such a widely experienced and well respected medical device executive to join our team and lead our international efforts to rapidly commercialise the VentrAssist(TM), " Ventracor's Chief Executive Officer and Managing Director, Colin Sutton, PhD, said. Mr. Crosby has been the CEO of four medical device companies in three countries and was most recently President and CEO of Ischemia Technologies, a Denver-based company that developed a new and proprietary diagnostic test for cardiac ischemia. Mr. Crosby is a member of the Board of Directors of Cardiac Science Inc (NASDAQ:DFIB), a developer and manufacturer of automatic external defibrillators (AED). Mr. Crosby also serves as Chairman of the Board of CardioComm Solutions, Inc, a Canadian developer of software products and Internet solutions for ECG management. He holds a Bachelor of Science in Electrical Engineering and a Master of Engineering Science from the University of Melbourne, Australia. Mr. Crosby will be based in the US. About Ventracor Ventracor (OTC:VTCRY)(ASX:VCR) is an international medical technology company that has developed a life-saving heart pump, the VentrAssist(TM) left ventricular assist system (LVAS), for patients in cardiac failure. The company is focused on commercializing the VentrAssist(TM) and bringing it to global markets in record time. Ventracor is confident of obtaining a significant share of the massive LVAS market, which independent analysts expect to be valued at between $US7.5 billion and $US12 billion per year. The VentrAssist(TM) LVAS The VentrAssist(TM) LVAS provides left heart support and is designed as a permanent alternative to a heart transplant. The titanium alloy pump is implanted below the diaphragm and is connected to the circulatory system using standard fabric tubes known as vascular grafts. The device itself is 2.5 inches (60 mm) in diameter and weighs just 10oz (298 grams). DATASOURCE: Ventracor Limited CONTACT: Ventracor Limited, +61-2-94063100, Web site: http://www.ventracor.com/

Copyright